NBT Bank N A NY raised its holdings in Celgene Co. (NASDAQ:CELG) by 11.9% during the third quarter, HoldingsChannel reports. The firm owned 20,247 shares of the biopharmaceutical company’s stock after buying an additional 2,153 shares during the period. NBT Bank N A NY’s holdings in Celgene were worth $2,953,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the business. BKD Wealth Advisors LLC raised its position in shares of Celgene by 2.7% during the 2nd quarter. BKD Wealth Advisors LLC now owns 3,921 shares of the biopharmaceutical company’s stock valued at $509,000 after acquiring an additional 104 shares in the last quarter. Hellman Jordan Management Co. Inc. MA acquired a new stake in shares of Celgene during the 2nd quarter valued at approximately $9,737,000. Berson & Corrado Investment Advisors LLC acquired a new stake in shares of Celgene during the 2nd quarter valued at approximately $1,365,000. First American Bank raised its position in shares of Celgene by 25.8% during the 2nd quarter. First American Bank now owns 49,835 shares of the biopharmaceutical company’s stock valued at $6,472,000 after acquiring an additional 10,217 shares in the last quarter. Finally, Charter Trust Co. raised its position in shares of Celgene by 8.5% during the 2nd quarter. Charter Trust Co. now owns 4,101 shares of the biopharmaceutical company’s stock valued at $532,000 after acquiring an additional 320 shares in the last quarter. 79.85% of the stock is currently owned by institutional investors.

Several equities research analysts recently issued reports on the company. UBS Group lowered Celgene from a “strong-buy” rating to a “market perform” rating and set a $160.00 price target on the stock. in a research report on Thursday, October 26th. BMO Capital Markets dropped their price target on Celgene from $163.00 to $148.00 and set an “outperform” rating on the stock in a research report on Friday, October 27th. Robert W. Baird lowered Celgene from an “outperform” rating to a “neutral” rating and dropped their price target for the company from $162.00 to $136.00 in a research report on Friday, October 20th. BTIG Research reissued a “hold” rating on shares of Celgene in a research report on Sunday, October 22nd. Finally, Vetr raised Celgene from a “buy” rating to a “strong-buy” rating and set a $144.39 price target on the stock in a research report on Monday, October 23rd. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and nineteen have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $131.18.

Celgene Co. (NASDAQ:CELG) opened at $106.00 on Monday. Celgene Co. has a 52 week low of $94.55 and a 52 week high of $147.17. The stock has a market capitalization of $83,455.59, a price-to-earnings ratio of 25.18, a PEG ratio of 0.68 and a beta of 1.77. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31.

Celgene (NASDAQ:CELG) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.87 by $0.04. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The company had revenue of $3.29 billion during the quarter, compared to analysts’ expectations of $3.42 billion. During the same quarter in the prior year, the business posted $1.58 earnings per share. The company’s revenue for the quarter was up 10.2% compared to the same quarter last year. research analysts expect that Celgene Co. will post 6.69 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This story was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this story on another publication, it was stolen and republished in violation of United States & international trademark & copyright laws. The correct version of this story can be accessed at https://www.dailypolitical.com/2018/01/15/celgene-co-celg-holdings-boosted-by-nbt-bank-n-a-ny.html.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.